United States securities and exchange commission logo

                             October 13, 2023

       Saqib Islam
       Chief Executive Officer
       SpringWorks Therapeutics, Inc.
       100 Washington Blvd
       Stamford, CT 06902

                                                        Re: SpringWorks
Therapeutics, Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2022
                                                            Filed February 28,
                                                            File No. 001-39044

       Dear Saqib Islam:

              We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comments.

              Please respond to this letter within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe a
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to this letter, we may have additional comments.

       Notes to the Consolidated Financial Statements

       Management's Discussion and Analysis
       Results of Operations
       Research and development expenses, page 107

   1.                                                   You disclose on page 7
that you have multiple product candidates with different
                                                        indications and on page
105 you state that you track external research and development
                                                        expenses on a
program-by-program basis. Please provide us, and confirm you will
                                                        disclosure in future
filings, a table which disaggregates external research and development
                                                        expense by program.
Include other line items in the table, as necessary, including any
                                                        amounts that are not
allocated, with the total reconciling to the amount on the Income
       10. License and Collaboration Agreements, page 135

   2.                                                   For your EGFR and TEAD
license agreements, please provide us proposed disclosure
                                                        which will be disclosed
in future filings regarding the specific terms of
 Saqib Islam
SpringWorks Therapeutics, Inc.
October 13, 2023
Page 2
         each agreement, including, as applicable, the amount of the upfront
payment, milestone
         payments disaggregated into the nature of each milestone, and the
royalty rate or range
         that does not exceed a ten point range.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       Please contact Mary Mast at 202-551-3613 or Daniel Gordon at
202-551-3486 with any

FirstName LastNameSaqib Islam                                Sincerely,
Comapany NameSpringWorks Therapeutics, Inc.
                                                             Division of
Corporation Finance
October 13, 2023 Page 2                                      Office of Life
FirstName LastName